Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658683 | 0.88 | BCL2 (0.46) | BCL2BCL2L1 | |
| SCHEMBL23323052 | 0.88 | BCL2 (0.46) | BCL2BCL2L1 | |
| SCHEMBL30415477 | 0.85 | BCL2 (0.55) | BCL2BCL2L1 | |
| SCHEMBL23323413 | 0.85 | BCL2 (0.55) | BCL2BCL2L1 | |
| SCHEMBL1702063 | 0.81 | BCL2 (0.50) | BCL2BCL2L1 | |
| SCHEMBL19867786 | 0.81 | BCL2 (0.50) | BCL2BCL2L1 | |
| SCHEMBL31058008 | 0.80 | BCL2 (0.43) | BCL2BCL2L1 | |
| SCHEMBL28839728 | 0.80 | BCL2 (0.51) | BCL2BCL2L1 | |
| SCHEMBL25204580 | 0.79 | BCL2 (0.47) | BCL2BCL2L1 | |
| SCHEMBL24005913 | 0.78 | BCL2 (0.48) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320208-A1 | Intermediates of Sonrotoclax and the Method of Preparing the Same | BEONE MEDICINES I GMBH (CH) | 2025-10-16 | — | — | US | disclosed |
| US-20250320207-A1 | Ketal Protected Intermediate for Sonrotoclax and Preparation Method Thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-16 | — | — | US | disclosed |
| US-20250320208-A1 | Intermediates of Sonrotoclax and the Method of Preparing the Same | BEONE MEDICINES I GMBH (CH) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320207-A1 | Ketal Protected Intermediate for Sonrotoclax and Preparation Method Thereof | KCNH3, KCNH1, KCNH2 | BCL2 468/4885BCL2L1 991/4885 |
| US-20250320208-A1 | Intermediates of Sonrotoclax and the Method of Preparing the Same | DNMT1, UQCRC2, TOP2B | BCL2 250/4885BCL2L1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.